206 related articles for article (PubMed ID: 9748120)
1. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
Siegel D; Franklin WA; Ross D
Clin Cancer Res; 1998 Sep; 4(9):2065-70. PubMed ID: 9748120
[TBL] [Abstract][Full Text] [Related]
2. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
4. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.
Malkinson AM; Siegel D; Forrest GL; Gazdar AF; Oie HK; Chan DC; Bunn PA; Mabry M; Dykes DJ; Harrison SD
Cancer Res; 1992 Sep; 52(17):4752-7. PubMed ID: 1324793
[TBL] [Abstract][Full Text] [Related]
5. An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues.
Gasdaska PY; Fisher H; Powis G
Cancer Res; 1995 Jun; 55(12):2542-7. PubMed ID: 7780966
[TBL] [Abstract][Full Text] [Related]
6. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
7. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.
Winski SL; Koutalos Y; Bentley DL; Ross D
Cancer Res; 2002 Mar; 62(5):1420-4. PubMed ID: 11888914
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of NQO1 in epithelial dysplasia and neoplasia and in donor eyes.
Schelonka LP; Siegel D; Wilson MW; Meininger A; Ross D
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1617-22. PubMed ID: 10845577
[TBL] [Abstract][Full Text] [Related]
9. Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
Lin YL; Ho IC; Su PF; Lee TC
Toxicol Appl Pharmacol; 2006 Aug; 214(3):309-17. PubMed ID: 16494910
[TBL] [Abstract][Full Text] [Related]
10. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
Vicent S; Garayoa M; López-Picazo JM; Lozano MD; Toledo G; Thunnissen FB; Manzano RG; Montuenga LM
Clin Cancer Res; 2004 Jun; 10(11):3639-49. PubMed ID: 15173070
[TBL] [Abstract][Full Text] [Related]
11. NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer.
Cui X; Jin T; Wang X; Jin G; Li Z; Lin L
Oncol Rep; 2014 Dec; 32(6):2589-95. PubMed ID: 25231218
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue.
Kolesar JM; Pritchard SC; Kerr KM; Kim K; Nicolson MC; McLeod H
Int J Oncol; 2002 Nov; 21(5):1119-24. PubMed ID: 12370763
[TBL] [Abstract][Full Text] [Related]
13. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
14. Arsenite and cadmium, but not chromium, induce NAD(P)H:quinone oxidoreductase 1 through transcriptional mechanisms, in spite of post-transcriptional modifications.
Elbekai RH; El-Kadi AO
Toxicol In Vitro; 2008 Aug; 22(5):1184-90. PubMed ID: 18474416
[TBL] [Abstract][Full Text] [Related]
15. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
Fryatt T; Pettersson HI; Gardipee WT; Bray KC; Green SJ; Slawin AM; Beall HD; Moody CJ
Bioorg Med Chem; 2004 Apr; 12(7):1667-87. PubMed ID: 15028260
[TBL] [Abstract][Full Text] [Related]
16. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
Newsome JJ; Swann E; Hassani M; Bray KC; Slawin AM; Beall HD; Moody CJ
Org Biomol Chem; 2007 May; 5(10):1629-40. PubMed ID: 17571194
[TBL] [Abstract][Full Text] [Related]
17. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.
Belinsky M; Jaiswal AK
Cancer Metastasis Rev; 1993 Jun; 12(2):103-17. PubMed ID: 8375015
[TBL] [Abstract][Full Text] [Related]
18. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
19. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
[TBL] [Abstract][Full Text] [Related]
20. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes.
McMahon M; Itoh K; Yamamoto M; Chanas SA; Henderson CJ; McLellan LI; Wolf CR; Cavin C; Hayes JD
Cancer Res; 2001 Apr; 61(8):3299-307. PubMed ID: 11309284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
